Document text
Principal Investigator: CYNTHIA E DUNBAR
Organization: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Fiscal Year: 2024
Award: $2,130,169
Funding agency: National Heart Lung and Blood Institute
My research group has worked for over 32 years in the laboratory and in the clinic to develop safe and effective gene therapies directed at hematopoietic stem and progenitor cells (HSPC). In the rhesus macaque model, shown to be the only predictive assay for human clinical results, we have focused on optimizing both lentiviral gene addition and gene editing therapies targeting hematopoietic stem and progenitor cells, and on understanding and enhancing the safety of established and new gene therapy systems.
Given the potential for genotoxicity with random integration of lentiviral vectors, and other drawbacks of semi-random gene addition as compared to targeted gene correction approaches, we have utilized the rhesus macaque to explore CRISPR/Cas9 genome editing and more recently base editing to create disease models and to develop gene editing therapies targeting HSPC. We have optimized CRISPR/Cas9 gene editing and base editing of rhesus CD34+ HSPC, initially knocking out loci via CRISPR/CAs-induced non-homologous end joining repair, creating loss-of function indels, and now focusing on improving the safety and efficacy of HDR-mediated gene correction and of single mutation-directed base editing. We have successfully engrafted 22 animals with gene-edited cells, with long-term levels of up to 70-90% for blood cells with targeted NHEJ indels.
We have focused on investigating the quantitative adverse impact of gene editing on the engraftment and long-term function of HSPCs in the macaque model. Using quantitative barcoding together with gene editing, we have demonstrated marked loss of functional HSPC numbers with both NHEJ but even more markedly HDR editing, and thus far less adverse impact on HSPCs with base editing, which does not result in double stranded DNA breaks.
We have created a robust macaque model of clonal hematopoiesis by targeting DNMT3, TET2 and ASXL1 with CRISPR/Cas9 mediated editing to create loss of function mutations. We have shown marked clonal expansion of TET2 mutated clones in three animals, and less marked expansion of DNMT2 or ASXL1 edited clones, and we have documented a highly inflammatory phenotype for TET2 mutant myeloid cells, relevant to the increased risk of cardiovascular disease in CHIP patients. We have multiple ongoing studies to investigate the biology of clonal expansion in these animals, and have shown that treatment with tociluzumab reverses or slows clonal expansion due to TET2 deficiency in this model (Shin et al, Blood, 2022). We hypothesized that clonal hematopoiesis accompanied by an inflammatory phenotype could be associated with severe COVID-19 disease, and carried out pilot studies investigating this using our macaque clonal hematopoiesis model, comparing outcomes of SARS-CoV-2 infection in clonal hematopoiesis versus control animals, documenting higher levels of virus in tissue and shed in the lungs (Shin et al, 2023).
We have also carried out a large scale targeted sequencing study of rhesus macaque blood cells from cohorts of aged animals, use deep error-corrected sequencing to look at 56 clonal hematopoiesis genes initially identified in aging humans. We have uncovered for the first time a natural animal model of clonal hematopoiesis, showing exactly the same genes mutated as in humans, in contrast to lack of such mutations in rodent models (Shin et al, Blood, 2022). We extended these studies to human cohorts in terms of analyzing the relationship between COVID-19 severity and the presence of clonal hematopoiesis, and in the largest and most definitive study to date, did not demonstrate an impact on COVID-19 severity (Zhou et al, Blood, 2022).
We have also developed a gene editing macaque model for RUNX1 deficiency in order to better understand the biology of the inherited marrow failure/leukemia predisposition syndrome and to assess the feasibility of gene therapies in correcting the phenotype, asking whether mutant vs normal cells predominate over time in a chimeric state. Mutant cells predominate, a concerning finding for gene therapies of this condition (Lee et al, Blood, 2023). This model also recapitulates the platelet and HSPC phenotype of human RUNX1 deficiency, in contrast to murine models.
A recent report linked clonal hematopoiesis to surprisingly a decreased risk of Alzheimer's disease, and postulated that CH myeloid cells were more potent in entering or functioning in the brain to prevent accumulation of amyloid or tau plaques. We have utilized our macaque CH model and control barcoded non-CH animals to investigate TET2 or other CH mutations results in higher replacement of microglial cells in the brain by analyzing purified macaque microglial cells for CH mutations compared to levels in blood myeloid cells. We have not found enhancement of microglial replacement by HSPC-derived cells in the setting of CH. Mechanistic studies are ongoing.
Terms: <AML1><AMLCR1><Aging><Alzheimer risk factor><Alzheimer's disease risk><Amyloid><Amyloid Substance><Animal Model><Animal Models and Related Studies><Animals><Bar Codes><Biology><Blood><Blood Cells><Blood Platelets><Blood Precursor Cell><Blood Reticuloendothelial System><Body Tissues><Brain><Brain Nervous System><CBFA2><CD34><CD34 gene><COVID disease severity><COVID severity><COVID-19><COVID-19 disease severity><COVID-19 infection><COVID-19 severity><COVID-19 virus infection><COVID19 disease severity><COVID19 infection><COVID19 severity><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CV-19><Cas nuclease technology><Cell Body><Cell Count><Cell Number><Cells><Clinic><Clinical><Clonal Expansion><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Control Animal><Coronavirus Infectious Disease 2019><DNA Double Strand Break><DNA Therapy><Disease><Disorder><Encephalon><Engineering><Engraftment><Failure><Gene Transfer Clinical><Generations><Genes><Genetic><Genetic Alteration><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic defect><HPCA1><Hematopoiesis><Hematopoietic Cellular Control Mechanisms><Hematopoietic Progenitor Cells><Hematopoietic stem cells><Hereditary><Hortega cell><Human><Inflammatory><Inherited><Knock-out><Knockout><Laboratories><Lentiviral Vector><Lentivirus Vector><Link><Lung><Lung Respiratory System><M mulatta><M. mulatta><MT-bound tau><Macaca><Macaca mulatta><Macaque><Marrow><Marrow platelet><Mediating><Microglia><Modeling><Modern Man><Modification><Mutate><Mutation><Myeloid Cells><NHEJ><Non-Homologous End Joining><Non-homologous DNA End Joining><Nonhomologous DNA End Joining><Nonhomologous End Joining><Normal Cell><Other Genetics><Outcome><PEBP2A2><PEBP2aB><Peripheral Blood Cell><Phenotype><Pilot Projects><Platelets><Pre-Clinical Model><Preclinical Models><Predisposition><Prognosis><RUNX1><RUNX1 gene><Reporting><Research><Rhesus><Rhesus Macaque><Rhesus Monkey><Rodent Model><SARS-CoV-2 disease severity><SARS-CoV-2 infection><SARS-CoV-2 severity><SARS-CoV2 infection><Safety><Severe acute respiratory syndrome coronavirus 2 infection><Susceptibility><Syndrome><System><Therapeutic Gene Editing><Thrombocytes><Time><Tissues><Toxic effect><Toxicities><Virus><Work><aged animal><aged animals><alzheimer risk><animal old age><barcode><base editing><blood cell formation><blood cell progenitor><blood progenitor><blood stem cell><blood-forming stem cell><cardiovascular disease risk><cardiovascular disorder risk><cohort><coronavirus disease 2019><coronavirus disease 2019 disease severity><coronavirus disease 2019 infection><coronavirus disease 2019 severity><coronavirus disease severity><coronavirus disease-19><coronavirus infectious disease-19><disease model><disorder model><elderly animal><functional loss><gene corrected><gene correction><gene editing method><gene editing methodology><gene editing strategy><gene editing techniques><gene repair therapy><gene therapy><gene-based therapy><gene-based treatment><gene-directed therapy><gene-editing approach><gene-editing therapy><gene-targeted therapy><gene-targeted treatment><genetic condition><genetic disorder><genetic therapy><genome editing><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genome mutation><genomic correction><genomic editing><genomic therapy><genotoxicity><gitter cell><hematopoietic progenitor><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><human disease><human model><improved><indel><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><insertion-deletion><insertion-deletion mutation><insertion/deletion><insertion/deletion mutation><lentiviral integration><lentivirus integration><leukemia><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><loss of function><loss of function mutation><mesoglia><microglial cell><microgliocyte><microtubule bound tau><microtubule-bound tau><model of animal><model of human><mouse model><murine model><mutant><old animals><patient prognosis><perivascular glial cell><pilot study><predictive assay><predictive test><prevent><preventing><pulmonary><repair><repaired><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 severity><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><targeted drug therapy><targeted drug treatments><targeted sequencing><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tau><tau Proteins><tau factor><therapeutic editing><therapeutic genome editing><τ Proteins>